AnaptysBio, Inc. Overview
Pro stress-test →AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company generates significant royalty revenue from out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), while advancing its own pipeline of immunomodulatory antibodies targeting immune checkpoint pathways.
Strategic Profile
Pro stress-test →The company recently announced intent to separate its biopharma operations from its substantial royalty assets by year-end 2026, enabling investors to align their investment philosophies with the strategic opportunities of each company. The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease; and ANB101, a BDCA2 modulator, in a Phase 1a trial.
Competitive Landscape
Pro stress-test →AnaptysBio competes in the immunomodulation space with diverse competitors developing checkpoint modulators and inflammatory disease treatments. Jemperli holds approximately 5% greater market share than Keytruda in the dMMR endometrial market, reflecting Jemperli's differentiated overall survival data. The company's own pipeline competes against established players in RA, celiac disease, and inflammatory skin conditions.
Industry Context
AnaptysBio, Inc. operates in Biotechnology - Clinical Stage Immunology Therapeutics.
Key facts
Headquarters: San Diego, United States